We use cookies to improve your website experience. To learn about our use of cookies and how you can manage your cookie settings, please see our Cookie Policy. By continuing to use the website, you consent to our use of cookies.
Pink Sheet is part of Pharma Intelligence UK Limited
This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.
This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183
Savara brings in initial $3.2mm in Series B round; adds $7.4mm
21 Mar 2013
Executive Summary
Pulmonary drug delivery firm Savara Pharmaceuticals has raised $3.2mm so far through its Series B venture round. (An extension to the financing is expected in the near future.) The Keiretsu Forum was joined by current shareholders, for a total of 117 investors. In addition to the new money, Savara raised $3.5mm via a recent bridge financing that converted to Series B shares and $1.9mm from an Emerging Technology Fund equity conversion. Proceeds will be put towards the advancement of AeroVanc through Phase IIa as the first inhaled antibiotic for Staphylococcus aureus in cystic fibrosis patients.
Deal Industry
Pharmaceuticals
Pharmaceuticals
Drug Delivery
Pulmonary
Biotechnology
Nanotechnology, Chips, etc.
Deal Status
Final
Deal Type
Financing
Venture Financing
Already a Biomedtracker subscriber?You have access to the full deal record through your subscription
Want to become a subscriber?Subscribers get more deal details, updates, deal financials and deal products.Questions?